Endurant Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-4,650
| Closed | -$448K | – | 4 |
|
|
2023
Q4 | $448K | Sell |
4,650
-174,918
| -97% | -$16.9M | 2.57% | 14 |
|
|
2023
Q3 | $15.9M | Buy |
179,568
+135,966
| +312% | +$12M | 14.27% | 1 |
|
|
2023
Q2 | $3.78M | Sell |
43,602
-212,014
| -83% | -$18.4M | 3.3% | 8 |
|
|
2023
Q1 | $24.9M | Buy |
255,616
+171,259
| +203% | +$16.7M | 12.77% | 1 |
|
|
2022
Q4 | $8.73M | Sell |
84,357
-61,017
| -42% | -$6.31M | 3.55% | 9 |
|
|
2022
Q3 | $12.3M | Buy |
145,374
+119,399
| +460% | +$10.1M | 4.01% | 8 |
|
|
2022
Q2 | $2.15M | Buy |
+25,975
| New | +$2.15M | 0.76% | 30 |
|
|
2020
Q2 | – | Sell |
-28,599
| Closed | -$2.42M | – | 60 |
|
|
2020
Q1 | $2.42M | Buy |
+28,599
| New | +$2.42M | 1.1% | 25 |
|
|
2018
Q1 | – | Sell |
-10,100
| Closed | -$901K | – | 75 |
|
|
2017
Q4 | $901K | Buy |
+10,100
| New | +$901K | 0.28% | 61 |
|
|
2017
Q3 | – | Sell |
-9,300
| Closed | -$845K | – | 87 |
|
|
2017
Q2 | $845K | Buy |
9,300
+4,200
| +82% | +$382K | 0.24% | 71 |
|
|
2017
Q1 | $448K | Buy |
+5,100
| New | +$448K | 0.14% | 79 |
|